Iovance Q2 Revenue Jumps 66% to $99M, Loss Narrows; Cash Runway Extended
IOVA has more than doubled off its 52-week low of $1.76.
Summary
Iovance's Q2 2026 revenue surged 66% to $99.3M on strong Amtagvi sales, with gross margin hitting 56% and net loss narrowing 58%. The company raised $49.6M via ATM, ending with $303.7M in cash, and disclosed a CMO departure.
Key Events · Earnings and Guidance · IOVA
-
Record Q2 Revenue
Product revenue reached $99.3 million, a 66% increase from Q2 2025, driven by Amtagvi infusions and Proleukin sales.
-
Gross Margin Expansion
Gross margin improved to 56% in Q2 2026, up from 18% a year ago, reflecting manufacturing efficiencies and lower period costs.
-
Net Loss Narrows
Net loss of $47.3 million was 58% lower than Q2 2025, as revenue growth outpaced expense increases.
-
ATM Proceeds Bolster Cash
The company raised $49.6 million in net proceeds from ATM sales of 14 million shares at $3.61 per share, ending the quarter with $303.7 million in cash and investments.
Analysis · IOVA · Life Sciences
Record quarterly revenue of $99.3 million, a 66% year-over-year surge, underscores the powerful demand for Amtagvi. Gross margin climbed to 56%, while the net loss contracted 58% to $47.3 million. Through its ATM program, the company raised $49.6 million during the quarter, closing with $303.7 million in cash and investments—enough to fund operations for at least 12 months. The filing also reveals the departure of the Chief Medical Officer and a related consulting agreement, along with updates on ongoing securities litigation. For a company trading near its 52-week high, the combination of accelerating commercial traction, improving margins, and a strengthened balance sheet marks a significant positive update.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 34.7% of the 1039 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IOVA was trading at $5.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $1.76 to $5.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.